Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIK2 | Q9H0K1 | 13/20 | 0.53 |
| ▸ | SIK3 | Q9Y2K2 | 13/20 | 0.53 |
| ▸ | ABL1 | P00519 | 12/20 | 0.53 |
| ▸ | SIK1 | P57059 | 11/20 | 0.53 |
| ▸ | SRC | P12931 | 6/20 | 0.49 |
| ▸ | KIT | P10721 | 4/20 | 0.49 |
| ▸ | PKMYT1 | Q99640 | 3/20 | 0.49 |
| ▸ | LCK | P06239 | 3/20 | 0.49 |
| ▸ | LYN | P07948 | 3/20 | 0.49 |
| ▸ | EPHB6 | O15197 | 2/20 | 0.49 |
| ▸ | EGFR | P00533 | 2/20 | 0.49 |
| ▸ | FYN | P06241 | 2/20 | 0.49 |
| ▸ | CSF1R | P07333 | 2/20 | 0.49 |
| ▸ | YES1 | P07947 | 2/20 | 0.49 |
| ▸ | RET | P07949 | 2/20 | 0.49 |
| ▸ | HCK | P08631 | 2/20 | 0.49 |
| ▸ | BCR | P11274 | 2/20 | 0.49 |
| ▸ | BRAF | P15056 | 2/20 | 0.49 |
| ▸ | EPHA1 | P21709 | 2/20 | 0.49 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14125141 | 0.97 | SIK2 (0.53) | SIK2SIK3ABL1SIK1SRC | |
| SCHEMBL2234513 | 0.84 | FGFR3 (0.49) | ABL1SRCKITLCKLYN | |
| SCHEMBL2236503 | 0.84 | FGFR1 (0.49) | ABL1SRCKITLCKLYN | |
| SCHEMBL2233335 | 0.82 | FGFR3 (0.59) | MAP3K7CYP3A4FGFR3 | |
| SCHEMBL14125196 | 0.82 | FGFR3 (0.46) | ABL1SRCKITLCKLYN | |
| SCHEMBL14125142 | 0.82 | FGFR1 (0.46) | ABL1SRCKITLCKLYN | |
| SCHEMBL14125140 | 0.81 | FGFR3 (0.55) | MAP3K7CYP3A4FGFR3 | |
| SCHEMBL2232928 | 0.78 | FGFR1 (0.51) | ABL1SRCKITLCKLYN | |
| SCHEMBL2232195 | 0.78 | ALK (0.50) | SRCEGFRMAP3K7FGFR1KCNH2 | |
| SCHEMBL2232666 | 0.78 | MAP3K7 (0.44) | ABL1SRCKITLCKLYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3141552-B1 | THIENOPYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE | HANMI PHARM IND CO LTD (KR) | 2019-04-17 | — | — | EP | claimed |
| US-10112954-B2 | Bicyclic heteroaryl derivatives having inhibitory activity for protein kinase | HANMI PHARM. CO., LTD. (KR) | 2018-10-30 | — | — | US | claimed |
| EP-3141552-A1 | THIENOPYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE | Hanmi Pharm. Co., Ltd. (KR) | 2017-03-15 | — | — | EP | claimed |
| EP-2528920-A2 | BICYCLIC HETEROARYL DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE | Hanmi Pharm. Co., Ltd. (KR) | 2012-12-05 | — | — | EP | claimed |
| US-20120302567-A1 | BICYCLIC HETEROARYL DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2012-11-29 | — | — | US | claimed |
| WO-2011093672-A2 | BICYCLIC HETEROARYL DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE | HANMI PHARM. CO., LTD. (KR) | 2011-08-04 | — | — | WO | claimed |
| EP-3141552-B1 | THIENOPYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE | HANMI PHARM IND CO LTD (KR) | 2019-04-17 | — | — | EP | disclosed |
| US-10112954-B2 | Bicyclic heteroaryl derivatives having inhibitory activity for protein kinase | HANMI PHARM. CO., LTD. (KR) | 2018-10-30 | — | — | US | disclosed |
| EP-3141552-A1 | THIENOPYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE | Hanmi Pharm. Co., Ltd. (KR) | 2017-03-15 | — | — | EP | disclosed |
| EP-2528920-A2 | BICYCLIC HETEROARYL DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE | Hanmi Pharm. Co., Ltd. (KR) | 2012-12-05 | — | — | EP | disclosed |
| US-20120302567-A1 | BICYCLIC HETEROARYL DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2012-11-29 | — | — | US | disclosed |
| US-20120302567-A1 | BICYCLIC HETEROARYL DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2012-11-29 | — | — | US | disclosed |
| WO-2011093672-A2 | BICYCLIC HETEROARYL DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE | HANMI PHARM. CO., LTD. (KR) | 2011-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120302567-A1 | BICYCLIC HETEROARYL DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE | CDK2, SBK3, CDK2AP1 | SIK2 91/4885SIK3 97/4885ABL1 206/4885 |
| US-10112954-B2 | Bicyclic heteroaryl derivatives having inhibitory activity for protein kinase | CDK2, SBK3, CDK2AP1 | SIK2 91/4885SIK3 97/4885ABL1 206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.